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In The Lancet, Leo Bonati and colleagues1 describe the 
results of the International Carotid Stenting Study 
(ICSS), a randomised controlled trial comparing 
carotid artery stenting and carotid endarterectomy. I 
compliment the authors for completing the largest trial 
of these two revascularisation strategies in patients 
with symptomatic carotid disease. In this primary 
analysis in 1713 patients, the main ﬁ nding was that, at 
a median follow-up of 4·2 years, the incidence of the 
primary endpoint—any fatal or disabling stroke—was 
virtually identical in the two groups; the diﬀ erence 
between the groups was only three events (52 vs 49). 
Beyond 30 days from the procedure, stenting and 
endarterectomy were similar in terms of prevention 
of any ipsilateral stroke (hazard ratio [HR] 1·29, 
95% CI 0·74–2·24). Nevertheless, an excess of any 
stroke was observed in the stenting group, with a 
5-year cumulative risk of 15·2% compared with 9·4% in 
the endarterectomy group (HR 1·71, 95% CI 1·28–2·30), 
although functional disability and quality of life did not 
diﬀ er between groups. This ﬁ nding is not unexpected, 
because an interim ICSS analysis reported an increased 
periprocedural stroke rate in the stenting group (HR 
for any stroke at 120 days after randomisation 1·92, 
95% CI 1·27–2·89).2
Meta-analyses of randomised trials suggest that, in 
the periprocedural phase, patients allocated to stenting 
have a signiﬁ cant excess of minor strokes, whereas 
patients undergoing endarterectomy have signiﬁ cantly 
more myocardial infarctions and cranial nerve injuries.3 
In patients younger than 70 years, 30-day rates of stroke 
and death are similar after stenting and endarterectomy, 
and in the long term the rates of death or disabling 
stroke are similar for the two procedures at all ages.4
The excess of periprocedural strokes has limited 
the acceptance of stenting as an alternative to 
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adverse events. T cells could be engineered to have 
enhanced persistence or to be resistant to hostile 
microenvironments. Likewise, the optimum position 
of CAR T-cell therapy in relation to existing therapies—
whether CAR T cells are best employed in frank 
relapse or to deepen remission, whether as a bridge 
to transplant or a standalone treatment—needs to be 
deﬁ ned. Such questions can only be answered in larger, 
well designed studies in deﬁ ned patient cohorts. More 
broadly, while drawing attention to the potential of 
CAR T-cell therapy, CD19 is a unique and ideal target 
antigen, and whether suitable targets can be identiﬁ ed 
to extend this approach to other cancers remains to be 
seen. Nonetheless, this approach is without question 
the most signiﬁ cant therapeutic advance in acute 
lymphoblastic leukaemia for a generation, and might 
represent the beginning of a new era of engineered 
T cells for cancer therapy.
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endarterectomy. Attention has been drawn to the 
fact that in four of the six major randomised trials (ie, 
those that enrolled more than 300 patients) of carotid 
stenting versus endarterectomy, interventionists with 
a lifetime experience of as few as ten carotid stenting 
procedures were included, and that for operators 
who did not meet this minimum requirement, tutor 
assistance was provided.5 In trials of endarterectomy 
compared with medical management done more 
than a decade earlier, the entry criteria for surgeons 
were much more stringent. For example, in the 
Asymptomatic Carotid Atherosclerosis Study (ACAS),6 
all endarterectomies performed at a candidate centre’s 
aﬃ  liated hospitals in the previous year were assessed. 
Once the centre was deemed to be qualiﬁ ed, each 
potential surgeon who wished to participate was 
required to submit the results of his or her 50 most 
recent consecutive endarterectomies. In ICSS, 38 CAS 
stenting procedures were aborted because of diﬃ  culty 
gaining access to the carotid stenosis compared with 
only two endarterectomy procedures, which might 
be interpreted as a marker of inadequate expertise, 
selection of patients, or both.2
In their discussion, Bonati and colleagues1 argue 
against the hypothesis that insuﬃ  cient endovascular 
expertise skewed trial outcomes. First, they point out 
that there were no diﬀ erences in event rates between 
centres supervised by tutors and those with experienced 
operators. Second, they note that even in larger centres 
the outcomes favoured endarterectomy. The deﬁ nition 
of an experienced operator in ICSS, however, was a 
lifetime case-load of at least 50 stenting procedures, 
of which ten or more had to have been in the carotid 
artery.2 Additionally, larger centres were deﬁ ned by the 
enrolment of 50 patients or more in the trial, which 
corresponds to a minimum average inclusion of ten 
patients per year. Finally, Bonati and colleagues quote 
a pooled analysis of three randomised trials, including 
ICSS, which concluded that stenting outcomes were 
not altered by the lifetime endovascular experience of 
the operators.7 Accordingly, no diﬀ erence was noted 
in patient outcomes after stratiﬁ cation for tertiles of 
lifetime stenting experience of the operators at the 
time of the procedure (0–16 cases, 17–37 cases, and 
more than 37 cases).7 Although from a methodological 
point of view the conclusion is sound, it needs to be 
underlined that two-thirds of the patients in these trials 
were treated by operators with lifetime experience of 
37 carotid stenting interventions or fewer at the time of 
the procedure.
No further studies randomly allocating symptomatic 
patients to carotid stenting or endarterectomy 
are in sight, although ECST-2 (ISRCTN97744893) 
should allow an indirect comparison between these 
two procedures. In asymptomatic patients, some 
information, albeit non-conclusive, should become 
available from the ACT-1 trial (NCT00106938), which 
has completed enrolment of around 1600 patients who 
were randomised 3:1 to stenting or endarterectomy. 
The ACST-2 study (NCT00883402) aims to recruit 
5000 asymptomatic patients, but no results will 
be available for several years. Finally, the SPACE-2 
(ISRCTN 78592017) trial, which is continuing, and 
CREST-2 (NCT02089217), for which enrolment 
should start by the end of 2014, will also allow only 
indirect comparisons between carotid stenting and 
endarterectomy in asymptomatic patients. On the 
basis of the current randomised evidence and this 
perspective with respect to new trials, the future of 
carotid stenting is uncertain.
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